Abstract
Original language | English |
---|---|
Journal | Cardiovasc. Diabetol. |
Volume | 19 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2020 |
Keywords
- Beck Depression Inventory
- Cardiovascular risk
- Depression
- Framingham risk score
- Obesity
- Proprotein Converatse Subtilisin/Kexin type 9
- antidepressant agent
- antihypertensive agent
- C reactive protein
- proprotein convertase 9
- serotonin noradrenalin reuptake inhibitor
- serotonin uptake inhibitor
- adult
- Article
- cardiovascular risk
- controlled study
- current smoker
- depression
- disease association
- enzyme analysis
- enzyme blood level
- enzyme linked immunosorbent assay
- female
- homeostasis model assessment
- human
- hypertension
- insulin resistance
- major clinical study
- male
- obesity
- retrospective study
Fingerprint
Dive into the research topics of 'Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance: Cardiovascular Diabetology'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance : Cardiovascular Diabetology. / Macchi, C.; Favero, C.; Ceresa, A.; Vigna, L.; Conti, D.M.; Pesatori, A.C.; Racagni, G.; Corsini, A.; Ferri, N.; Sirtori, C.R.; Buoli, M.; Bollati, V.; Ruscica, M.
In: Cardiovasc. Diabetol., Vol. 19, No. 1, 2020.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance
T2 - Cardiovascular Diabetology
AU - Macchi, C.
AU - Favero, C.
AU - Ceresa, A.
AU - Vigna, L.
AU - Conti, D.M.
AU - Pesatori, A.C.
AU - Racagni, G.
AU - Corsini, A.
AU - Ferri, N.
AU - Sirtori, C.R.
AU - Buoli, M.
AU - Bollati, V.
AU - Ruscica, M.
N1 - Cited By :1 Export Date: 5 March 2021 CODEN: CDAIA Correspondence Address: Ruscica, M.; Department of Pharmacological and Biomolecular Sciences, Italy; email: massimiliano.ruscica@unimi.it Correspondence Address: Bollati, V.; EPIGET Department of Clinical Sciences and Community Health, Italy; email: valentina.bollati@unimi.it Chemicals/CAS: C reactive protein, 9007-41-4; proprotein convertase 9; serine protease HTRA1; serine proteinase Funding details: European Research Council, ERC, 413, ERC-2011-StG 282, ERC-2011-StG 282,413 Funding details: Fondazione Cariplo, 2015-0552, 2018-0511, PSR 2018 Funding text 1: This study was partially supported by Cariplo Foundation (2015-0552 and 2018-0511 to MR), University of Milan Intramural Grant PSR 2018 to MR and EU Programme ‘Ideas’, European Research Council (ERC-2011-StG 282,413 to VB). Grants from MIUR Progetto Eccellenza. Acknowledgements References: Roth, G.A., Forouzanfar, M.H., Moran, A.E., Barber, R., Nguyen, G., Feigin, V.L., Naghavi, M., Murray, C.J., Demographic and epidemiologic drivers of global cardiovascular mortality (2015) N Engl J Med, 372 (14), pp. 1333-1341. , COI: 1:CAS:528:DC%2BC2MXns1CltL0%3D; Mach, F., Baigent, C., Catapano, A.L., Koskinas, K.C., Casula, M., Badimon, L., Chapman, M.J., Ference, B.A., ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk (2019) Eur Heart J, 2019; Khan, S.S., Ning, H., Wilkins, J.T., Allen, N., Carnethon, M., Berry, J.D., Sweis, R.N., Lloyd-Jones, D.M., Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity (2018) JAMA Cardiol, 3 (4), pp. 280-287; Hare, D.L., Toukhsati, S.R., Johansson, P., Jaarsma, T., Depression and cardiovascular disease: a clinical review (2014) Eur Heart J, 35 (21), pp. 1365-1372; Luppino, F.S., de Wit, L.M., Bouvy, P.F., Stijnen, T., Cuijpers, P., Penninx, B.W., Zitman, F.G., Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies (2010) Arch Gen Psychiatry, 67 (3), pp. 220-229; The Global Burdenof Disease: 2004 Update. Geneva. In.; Vaccarino, V., Badimon, L., Bremner, J.D., Cenko, E., Cubedo, J., Dorobantu, M., Duncker, D.J., Milicic, D., Depression and coronary heart disease: 2018 ESC position paper of the working group of coronary pathophysiology and microcirculation (2019) Developed under the Auspices of the ESC Committee for Practice Guidelines. Eur Heart J; Gan, Y., Gong, Y., Tong, X., Sun, H., Cong, Y., Dong, X., Wang, Y., Deng, J., Depression and the risk of coronary heart disease: a meta-analysis of prospective cohort studies (2014) BMC Psychiatry, 14, p. 371; Nicholson, A., Kuper, H., Hemingway, H., Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies (2006) Eur Heart J, 27 (23), pp. 2763-2774; Jha, M.K., Qamar, A., Vaduganathan, M., Charney, D.S., Murrough, J.W., Screening and management of depression in patients with cardiovascular disease: JACC State-of-the-Art Review (2019) J Am Coll Cardiol, 73 (14), pp. 1827-1845; Kim, J.M., Stewart, R., Lee, Y.S., Lee, H.J., Kim, M.C., Kim, J.W., Kang, H.J., Shin, I.S., Effect of Escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial (2018) JAMA, 320 (4), pp. 350-358. , COI: 1:CAS:528:DC%2BC1cXhsVehtrrI; Sattar, N., Revisiting the links between glycaemia, diabetes and cardiovascular disease (2013) Diabetologia, 56 (4), pp. 686-695. , COI: 1:CAS:528:DC%2BC3sXjslehsL8%3D; Mezuk, B., Eaton, W.W., Albrecht, S., Golden, S.H., Depression and type 2 diabetes over the lifespan: a meta-analysis (2008) Diab Care, 31 (12), pp. 2383-2390; Moulton, C.D., Pickup, J.C., Ismail, K., The link between depression and diabetes: the search for shared mechanisms (2015) Lancet Diabetes Endocrinol, 3 (6), pp. 461-471; Macchi, C., Banach, M., Corsini, A., Sirtori, C.R., Ferri, N., Ruscica, M., Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels–experimental and clinical approaches with lipid-lowering agents (2019) Eur J Prev Cardiol, 26 (9), pp. 930-949. , COI: 1:STN:280:DC%2BB3cfkslCgsw%3D%3D; Cheng, J.M., Oemrawsingh, R.M., Garcia-Garcia, H.M., Boersma, E., van Geuns, R.J., Serruys, P.W., Kardys, I., Akkerhuis, K.M., PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study (2016) Atherosclerosis, 248, pp. 117-122. , COI: 1:CAS:528:DC%2BC28Xks1yktb0%3D; Ferri, N., Marchiano, S., Tibolla, G., Baetta, R., Dhyani, A., Ruscica, M., Uboldi, P., Corsini, A., PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement (2016) Atherosclerosis, 253, pp. 214-224. , COI: 1:CAS:528:DC%2BC28Xht1GhurfM; Costet, P., Cariou, B., Lambert, G., Lalanne, F., Lardeux, B., Jarnoux, A.L., Grefhorst, A., Krempf, M., Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c (2006) J Biol Chem, 281 (10), pp. 6211-6218. , COI: 1:CAS:528:DC%2BD28XhvFOhtbY%3D; Myocardial Infarction Genetics, C., Kathiresan, S., Voight, B.F., Purcell, S., Musunuru, K., Ardissino, D., Mannucci, P.M., Samani, N.J., Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants (2009) Nat Genet, 41 (3), pp. 334-341; Ridker, P.M., Rifai, N., Bradwin, G., Rose, L., Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events (2016) Eur Heart J, 37 (6), pp. 554-560. , COI: 1:CAS:528:DC%2BC1cXjsFalu7Y%3D; Gencer, B., Montecucco, F., Nanchen, D., Carbone, F., Klingenberg, R., Vuilleumier, N., Aghlmandi, S., Auer, R., Prognostic value of PCSK9 levels in patients with acute coronary syndromes (2016) Eur Heart J, 37 (6), pp. 546-553. , COI: 1:CAS:528:DC%2BC1cXjsFaksb0%3D; Leander, K., Malarstig, A., Van’t Hooft, F.M., Hyde, C., Hellenius, M.L., Troutt, J.S., Konrad, R.J., de Faire, U., Circulating proprotein convertase subtilisin/Kexin Type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors (2016) Circulation, 133 (13), pp. 1230-1239. , COI: 1:CAS:528:DC%2BC28XltFGgtrY%3D; Macchi, C., Ferri, N., Favero, C., Cantone, L., Vigna, L., Pesatori, A.C., Lupo, M.G., Bollati, V., Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals (2019) Eur J Prev Cardiol, 26 (6), pp. 578-588; Lee, J.S., Rosoff, D., Luo, A., Longley, M., Phillips, M., Charlet, K., Muench, C., Lohoff, F.W., PCSK9 is increased in cerebrospinal fluid of individuals with alcohol use disorder (2019) Alcohol Clin Exp Res, 43 (6), pp. 1163-1169. , COI: 1:CAS:528:DC%2BC1MXhtFSrtLzN, PID: 6696932; Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Varigos, J., Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study (2004) Lancet, 364 (9438), pp. 937-952; Ellins, E.A., Shipley, M.J., Rees, D.A., Kemp, A., Deanfield, J.E., Brunner, E.J., Halcox, J.P., Associations of depression-anxiety and dyslipidaemia with subclinical carotid arterial disease: Findings from the Whitehall II Study (2019) Eur J Prev Cardiol; O’Leary, D.H., Polak, J.F., Kronmal, R.A., Manolio, T.A., Burke, G.L., Wolfson, S.K., Jr., Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults (1999) N Engl J Med, 340 (1), pp. 14-22; Wysokinski, A., Strzelecki, D., Kloszewska, I., Levels of triglycerides, cholesterol, LDL, HDL and glucose in patients with schizophrenia, unipolar depression and bipolar disorder (2015) Diabetes Metab Syndr, 9 (3), pp. 168-176; Wagner, C.J., Musenbichler, C., Bohm, L., Farber, K., Fischer, A.I., von Nippold, F., Winkelmann, M., Kornhuber, J., LDL cholesterol relates to depression, its severity, and the prospective course (2019) Prog Neuropsychopharmacol Biol Psychiatry, 92, pp. 405-411. , COI: 1:CAS:528:DC%2BC1MXks1yrtbg%3D; Chang, N.T., Su, T.C., Investigating the association between familial hypercholesterolemia and perceived depression (2019) Atheroscler Suppl, 36, pp. 31-36; Tang, B., Yuan, S., Xiong, Y., He, Q., Larsson, S.C., Major depressive disorder and cardiometabolic diseases: a bidirectional Mendelian randomisation study (2020) Diabetologia, 63 (7), pp. 1305-1311; Reilly, M.P., Wolfe, M.L., Rhodes, T., Girman, C., Mehta, N., Rader, D.J., Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis (2004) Circulation, 110 (7), pp. 803-809. , COI: 1:CAS:528:DC%2BD2cXmtlOqtL0%3D; Bollati, V., Iodice, S., Favero, C., Angelici, L., Albetti, B., Cacace, R., Cantone, L., De Giorgio, B., Susceptibility to particle health effects, miRNA and exosomes: rationale and study protocol of the SPHERE study (2014) BMC Public Health, 14, p. 1137; Smarr, K.L., Keefer, A.L., Measures of depression and depressive symptoms: beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9) (2011) Arthritis Care Res, 63, pp. S454-S466; Hayes, A.F., Scharkow, M., The relative trustworthiness of inferential tests of the indirect effect in statistical mediation analysis: does method really matter? (2013) Psychol Sci, 24 (10), pp. 1918-1927; Ruscica, M., Ferri, N., Fogacci, F., Rosticci, M., Botta, M., Marchiano, S., Magni, P., Borghi, C., Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study (2017) J Am Heart Assoc, 6 (5); Tyrrell, J., Mulugeta, A., Wood, A.R., Zhou, A., Beaumont, R.N., Tuke, M.A., Jones, S.E., Sharp, S., Using genetics to understand the causal influence of higher BMI on depression (2018) Int J Epidemiol; Milaneschi, Y., Simmons, W.K., van Rossum, E.F.C., Penninx, B.W., Depression and obesity: evidence of shared biological mechanisms (2019) Mol Psychiatry, 24 (1), pp. 18-33. , COI: 1:CAS:528:DC%2BC1cXht1CjsLbN; Siu, A.L., Force, U.S.P.S.T., Bibbins-Domingo, K., Grossman, D.C., Baumann, L.C., Davidson, K.W., Ebell, M., Herzstein, J., Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement (2016) JAMA, 315 (4), pp. 380-387; Spitzer, R.L., Kroenke, K., Williams, J.B., Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire (1999) JAMA, 282 (18), pp. 1737-1744; Rubin, R.R., Peyrot, M., Gaussoin, S.A., Espeland, M.A., Williamson, D., Faulconbridge, L.F., Wadden, T.A., Evans-Hudnall, G., Four-year analysis of cardiovascular disease risk factors, depression symptoms, and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes (2013) Diab Care, 36 (5), pp. 1088-1094. , COI: 1:CAS:528:DC%2BC3sXnslWrs7w%3D; Westhoff-Bleck, M., Winter, L., Aguirre Davila, L., Herrmann-Lingen, C., Treptau, J., Bauersachs, J., Bleich, S., Kahl, K.G., Diagnostic evaluation of the hospital depression scale (HADS) and the Beck depression inventory II (BDI-II) in adults with congenital heart disease using a structured clinical interview: Impact of depression severity (2019) Eur J Prev Cardiol; Beck, A.T., Steer, R.A., Brown, G.K., BDI-II (1996) Beck Depression Inventory: Manual; Albert, P.R., Why is depression more prevalent in women? (2015) J Psychiatry Neurosci, 40 (4), pp. 219-221; Lichtman, J.H., Bigger, J.T., Jr., Blumenthal, J.A., Frasure-Smith, N., Kaufmann, P.G., Lesperance, F., Mark, D.B., Froelicher, E.S., Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association (2008) Circulation, 118 (17), pp. 1768-1775; Lyra, E.S.N.M., Lam, M.P., Soares, C.N., Munoz, D.P., Milev, R., De Felice, F.G., Insulin resistance as a shared pathogenic mechanism between depression and Type 2 diabetes (2019) Front Psychiatry, 10, p. 57; Bonora, E., Formentini, G., Calcaterra, F., Lombardi, S., Marini, F., Zenari, L., Saggiani, F., Raffaelli, A., HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study (2002) Diab Care, 25 (7), pp. 1135-1141; Seidah, N.G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S.B., Stifani, S., Basak, A., Chretien, M., The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation (2003) Proc Natl Acad Sci U S A, 100 (3), pp. 928-933. , COI: 1:CAS:528:DC%2BD3sXhtF2gsL4%3D; Cesaro, A., Bianconi, V., Gragnano, F., Moscarella, E., Fimiani, F., Monda, E., Scudiero, O., Calabro, P., Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition (2020) Biofactors, 46 (3), pp. 367-380. , COI: 1:CAS:528:DC%2BB3cXhvVekt70%3D; O’Connell, E.M., Lohoff, F.W., Proprotein convertase subtilisin/Kexin Type 9 (PCSK9) in the brain and relevance for neuropsychiatric disorders (2020) Front Neurosci, 14, p. 609; Lohoff, F.W., Lipid-lowering drug effects beyond the cardiovascular system: relevance for neuropsychiatric disorders (2018) Int J Neuropsychopharmacol, 21 (12), pp. 1076-1078. , COI: 1:CAS:528:DC%2BC1MXhsFeitLfN; Nelson, C.P., Lai, F.Y., Nath, M., Ye, S., Webb, T.R., Schunkert, H., Samani, N.J., Genetic assessment of potential long-term on-target side effects of PCSK9 (proprotein convertase subtilisin/Kexin Type 9) inhibitors (2019) Circ Genom Precis Med, 12 (1). , COI: 1:CAS:528:DC%2BC1MXitVygtrY%3D; Alghamdi, J., Matou-Nasri, S., Alghamdi, F., Alghamdi, S., Alfadhel, M., Padmanabhan, S., Risk of neuropsychiatric adverse effects of lipid-lowering drugs: a mendelian randomization study (2018) Int J Neuropsychopharmacol, 21 (12), pp. 1067-1075. , COI: 1:CAS:528:DC%2BC1MXhsFeitLzK; Calabro, P., Gragnano, F., Pirro, M., Cognitive function in a Randomized Trial of evolocumab (2017) N Engl J Med, 377 (20), pp. 1996-1997; Giugliano, R.P., Sabatine, M.S., Ott, B.R., Cognitive Function in a Randomized Trial of Evolocumab (2017) N Engl J Med, 377 (20), p. 1997; Ray, K.K., Del Prato, S., Muller-Wieland, D., Cariou, B., Colhoun, H.M., Tinahones, F.J., Domenger, C., Samuel, R., Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies (2019) Cardiovasc Diabetol, 18 (1), p. 149; Vlachopoulos, C., Terentes-Printzios, D., Georgiopoulos, G., Skoumas, I., Koutagiar, I., Ioakeimidis, N., Stefanadis, C., Tousoulis, D., Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: a systematic review and meta-analysis (2016) Atherosclerosis, 252, pp. 50-60. , COI: 1:CAS:528:DC%2BC28XhtlWjtLjO; Guo, W., Gong, Y., Li, J., Qin, P., Lu, J., Li, X., Zhu, W., Zhang, Q., Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus (2019) Nutr Metab Cardiovasc Dis, 29 (8), pp. 815-821. , COI: 1:CAS:528:DC%2BC1MXosVOqtbc%3D; Pott, J., Schlegel, V., Teren, A., Horn, K., Kirsten, H., Bluecher, C., Kratzsch, J., Burkhardt, R., Genetic regulation of PCSK9 (proprotein convertase subtilisin/Kexin Type 9) plasma levels and its impact on atherosclerotic vascular disease phenotypes (2018) Circ Genom Precis Med, 11 (5). , COI: 1:CAS:528:DC%2BC1cXhtV2mt7bI; Rao, A.S., Lindholm, D., Rivas, M.A., Knowles, J.W., Montgomery, S.B., Ingelsson, E., Large-scale phenome-wide association study of PCSK9 variants demonstrates protection against ischemic stroke (2018) Circ Genom Precis Med, 11 (7). , COI: 1:CAS:528:DC%2BC1cXhtl2jsrjF; Tang, Y., Li, S.L., Hu, J.H., Sun, K.J., Liu, L.L., Xu, D.Y., Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes (2020) Cardiovasc Diabetol, 19 (1), p. 33. , COI: 1:CAS:528:DC%2BB3cXltFSisL8%3D; Dozio, E., Ruscica, M., Vianello, E., Macchi, C., Sitzia, C., Schmitz, G., Tacchini, L., Corsi Romanelli, M.M., PCSK9 expression in epicardial adipose tissue: molecular association with local tissue inflammation (2020) Mediators Inflamm, 2020, p. 1348913. , PID: 7292972; Blanchard, C., Ledoux, S., Verhaegen, A., Wargny, M., Letessier, E., Stepanian, A., Huten, N., Le Bras, M., Roux-en-Y gastric bypass, but not sleeve gastrectomy, decreases plasma PCSK9 levels in morbidly obese patients (2020) Diabetes Metab; Zenti, M., Lupo, M., De Martin, S., Altomri, A., Galvan, S., Aventaggiato, M., Maneschi, C., Battistoni, M., Impact of bariatric surgery-induced weight loss on circulating PCSK9 levels in obese patients (2020) Nutr Metab Cardiovasc Dis; Lakoski, S.G., Lagace, T.A., Cohen, J.C., Horton, J.D., Hobbs, H.H., Genetic and metabolic determinants of plasma PCSK9 levels (2009) J Clin Endocrinol Metab, 94 (7), pp. 2537-2543. , COI: 1:CAS:528:DC%2BD1MXosl2ksLo%3D; Ramin-Mangata, S., Wargny, M., Pichelin, M., Le May, C., Thedrez, A., Blanchard, V., Nativel, B., Lotufo, P.A., Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes (2020) Atherosclerosis, 293, pp. 49-56. , COI: 1:CAS:528:DC%2BC1MXitlOmurzO; Caselli, C., Del Turco, S., Ragusa, R., Lorenzoni, V., De Graaf, M., Basta, G., Scholte, A., Neglia, D., Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina (2019) Cardiovasc Diabetol, 18 (1), p. 144; Kotseva, K., De Backer, G., De Bacquer, D., Ryden, L., Hoes, A., Grobbee, D., Maggioni, A., Abreu, A., Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry (2019) Eur J Prev Cardiol, 26 (8), pp. 824-835; Vrany, E.A., Berntson, J.M., Khambaty, T., Stewart, J.C., Depressive symptoms clusters and insulin resistance: race/ethnicity as a moderator in 2005-2010 NHANES Data (2016) Ann Behav Med, 50 (1), pp. 1-11; Essmat, N., Soliman, E., Mahmoud, M.F., Mahmoud, A.A.A., Antidepressant activity of anti-hyperglycemic agents in experimental models: a review (2020) Diabetes Metab Syndr, 14 (5), pp. 1179-1186
PY - 2020
Y1 - 2020
N2 - Background: Depression and cardiovascular disease (CVD) are among the most common causes of disability in high-income countries, depression being associated with a 30% increased risk of future CV events. Depression is twice as common in people with diabetes and is associated with a 60% rise in the incidence of type 2 diabetes, an independent CVD risk factor. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of low-density lipoprotein cholesterol, has been related to a large number of CV risk factors, including insulin resistance. Aim of this study was to investigate whether the presence of depression could affect PCSK9 levels in a population of obese subjects susceptible to depressive symptoms and how these changes may mediate a pre-diabetic risk. Results: In 389 obese individuals, the Beck Depression Inventory (BDI-II) was significantly associated with PCSK9 levels. For every one-unit increment in BDI-II score, PCSK9 rose by 1.85 ng/mL. Depression was associated also with the HOMA-IR (homeostatic model assessment index of insulin resistance), 11% of this effect operating indirectly via PCSK9. Conclusions: This study indicates a possible mechanism linking depression and insulin resistance, a well-known CV risk factor, providing evidence for a significant role of PCSK9. © 2020, The Author(s).
AB - Background: Depression and cardiovascular disease (CVD) are among the most common causes of disability in high-income countries, depression being associated with a 30% increased risk of future CV events. Depression is twice as common in people with diabetes and is associated with a 60% rise in the incidence of type 2 diabetes, an independent CVD risk factor. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of low-density lipoprotein cholesterol, has been related to a large number of CV risk factors, including insulin resistance. Aim of this study was to investigate whether the presence of depression could affect PCSK9 levels in a population of obese subjects susceptible to depressive symptoms and how these changes may mediate a pre-diabetic risk. Results: In 389 obese individuals, the Beck Depression Inventory (BDI-II) was significantly associated with PCSK9 levels. For every one-unit increment in BDI-II score, PCSK9 rose by 1.85 ng/mL. Depression was associated also with the HOMA-IR (homeostatic model assessment index of insulin resistance), 11% of this effect operating indirectly via PCSK9. Conclusions: This study indicates a possible mechanism linking depression and insulin resistance, a well-known CV risk factor, providing evidence for a significant role of PCSK9. © 2020, The Author(s).
KW - Beck Depression Inventory
KW - Cardiovascular risk
KW - Depression
KW - Framingham risk score
KW - Obesity
KW - Proprotein Converatse Subtilisin/Kexin type 9
KW - antidepressant agent
KW - antihypertensive agent
KW - C reactive protein
KW - proprotein convertase 9
KW - serotonin noradrenalin reuptake inhibitor
KW - serotonin uptake inhibitor
KW - adult
KW - Article
KW - cardiovascular risk
KW - controlled study
KW - current smoker
KW - depression
KW - disease association
KW - enzyme analysis
KW - enzyme blood level
KW - enzyme linked immunosorbent assay
KW - female
KW - homeostasis model assessment
KW - human
KW - hypertension
KW - insulin resistance
KW - major clinical study
KW - male
KW - obesity
KW - retrospective study
U2 - 10.1186/s12933-020-01158-6
DO - 10.1186/s12933-020-01158-6
M3 - Article
VL - 19
JO - Cardiovasc. Diabetol.
JF - Cardiovasc. Diabetol.
SN - 1475-2840
IS - 1
ER -